Head-to-head dispatch
Layla vs Wisp
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…
Marked down on: Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
Desk Score
Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
Marked down on: The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
Layla takes this head-to-head with the higher Desk Score, 70/100 (C) against 69/100 (C) for Wisp. Wisp still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Layla
70/100
C
Wisp
69/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Layla | Wisp |
|---|---|---|
| Semaglutide | $237/mo (all doses, compounded) | $225/mo (compounded oral) |
| Tirzepatide | $199/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | People wanting oral or injectable semaglutide with a brand-inclusive glp-1 upgrade path. | Readers who want branded injectables plus a sublingual semaglutide alternative. |
| Desk Score | 70/100C | 69/100C |
The verdict
Desk pick — LaylaLayla takes this head-to-head with the higher Desk Score, 70/100 (C) against 69/100 (C) for Wisp. Wisp still holds its ground where its strengths line up with yours.
Choose Layla if…
People wanting oral or injectable semaglutide with a brand-inclusive glp-1 upgrade path.
$237/mo (all doses, compounded) sema · $199/mo (all doses, compounded) tirz · Coverage not published
Choose Wisp if…
Readers who want branded injectables plus a sublingual semaglutide alternative.
$225/mo (compounded oral) sema · Not disclosed tirz · Coverage not published
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Layla · Wisp.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Layla vs CoreAge Rx
- Wisp vs Vaylen
- Layla vs Strut Health
- Wisp vs Ondra Health
- Layla vs Invigor Medical
- Wisp vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.